Harwin Peter Evan's Form 4 filing
Zenas BioPharma, Inc.ZBIO · filed Apr 1, 2026
- Accession no.
- 0001104659-26-038546
- Filed
- Apr 1, 2026, 4:30 PM ET
- Trade date
- Mar 31, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $3.00M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harwin Peter EvanCIK 0001663607 | Director |
| Fairmount Healthcare Fund II L.P.CIK 0001769651 | Director |
| Fairmount Funds Management LLCCIK 0001802528 | Director |
| Kiselak TomasCIK 0001830177 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Common Stock | PPurchaseAcquired | +150,000 | $20.00 | +$3,000,000 | 2,359,025 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is also a Managing Member of Fairmount.